You searched for "IVTA"
IVTA use in Behçet’s disease
This study aimed to evaluate the efficacy and safety of intravitreal triamcinolone acetonide (IVTA) injection (4mg/0.1ml) in controlling posterior segment inflammation in patients with Behçet’s disease. Medical records of consecutive patients diagnosed with Behçet’s who underwent IVTA between July 2005...
IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis
1 August 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...
Cytomegalovirus retinitis post intravitreal triamcinolone in an immunocompetent patient with juvenile glaucoma
1 December 2014
| Eneh Jones-Odeh, KS Lim, MR Stanford
|
EYE - Cataract, EYE - Cornea, EYE - General, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal
Figure 1: Fundus photograph shows active CMV retinitis four weeks after IVTA in the right eye. Figure 2: Fundus photograph of the left eye with no CMV retinitis; atrophic disc as a result of juvenile glaucoma. Case report A 29-year-old...
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
7 April 2021
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
Evaluation of Optive® in ocular discomfort after anti-VEGF intravitreal injection
1 October 2021
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Artificial tear, Intravitreal injection therapy, Ocular discomfort, Ocular surface
In this study the authors prospectively evaluated the efficacy of Optive® eye drops after in full, then abbreviation - intravitreal injection (IVT). Patients naïve to IVT were included in the study. No artificial tear treatment was prescribed after the first...
An uncommon late postoperative complication of combined cataract surgery and intravitreal triamcinolone injection
1 December 2014
| Pouya Alaghband, Ambreen Kalhoro, Toams Cudrnak, Ishtyak Mahomed, Nigel James
|
EYE - Cataract, EYE - Cornea, EYE - General, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal
Case report A 64-year-old female with diabetic maculopathy (DMO) underwent phacoemulsification with intraocular lens (IOL) implantation in her right eye combined with intravitreal triamcinolone (IVTA). Diabetes control was poor with HbA1c (IFCC) of 119mmol/mol and blood sugar level of 27mmol/L....
Steroid treatment for pseudophakic cystoid macular oedema
1 October 2021
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Cystoid macular edema, intravitreal steroids, triamcinolone
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
Detection of antiranibizumab antibodies in exudative AMD
1 December 2014
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this study the authors aimed to detect immune response to ranibizumab treatment in wet age-related macular degeneration (AMD). An ELISA was employed to quantify the anti-ranibizumab titre which was compared against the control anti-abciximab titre. Titres of anti-ranibizumab antibodies...
Laser photocoagulation vs. intravitreal (IVT) aflibercept for ROP
The efficacy, recurrence rate and requirement for additional treatment were compared between laser photocoagulation and IVT of 1mg/0.025ml aflibercept in the treatment of retinopathy of prematurity (ROP). The study included 27 babies (51 eyes) who completed a follow-up period after...The role of inflammation in the pathophysiology of DMO
1 February 2016
| Fiona Harris, Spyridon Chalkiadakis, Simon Taylor (Prof)
|
EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...
Diabetic Macular Oedema
1 December 2013
| Pouya Alaghband
Diabetes mellitus is a metabolic disorder that affects the metabolism of all three categories of carbohydrates, lipids and proteins. This condition is characterised by chronic hyperglycaemia [1]. This can cause end organ damage. The estimated worldwide diabetes prevalence for 2010...
Celebrating eight years of the nurse-led intravitreal injection service
4 February 2021
| Adam Mapani, Robin Hamilton, Jonah Nago, Gavin Kissoondeeal, Bhavin Maru, Musa Sanyang, Rankin Pacheco, Helen Carpenter, Julie Sharma, Mary Masih, Tracy Luckett, Kate Falkner
|
EYE - Vitreo-Retinal, EYE - General
Moorfields Eye Hospital NHS Foundation Trust in London celebrated the eighth year of its nurse-led intravitreal (IVT) injection service in 2020. In collaboration with Beaver-Visitec International (BVI), Moorfields’ comprehensive one-day course for non-medical staff has blossomed into a thriving success....
